Navigation Links
HeartWare to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/4/2011

FRAMINGHAM, Mass. and SYDNEY, Jan. 4, 2011 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the 29th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. Pacific Time on Monday, January 10, 2011. The conference is being held January 10-13, 2011 at the Westin St. Francis in San Francisco.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  An archived replay of the presentation will also be available shortly after the presentation time for a period of 90 days.

About HeartWare InternationalHeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.For further information:Christopher TaylorHeartWare International, Inc.Email: ctaylor@heartwareinc.comPhone: +1 508 739 0864
'/>"/>

SOURCE HeartWare Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Files PMA Application for FDA Approval of the HeartWare® Ventricular Assist System for a Bridge-to-Transplant Indication
2. HeartWare International, Inc. Announces Completion of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
3. HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
4. HeartWare International, Inc. Announces Concurrent Public Offerings of Convertible Senior Notes and Common Stock
5. HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference
6. HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial, ADVANCE
7. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
8. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare to Report Financial Results for Third Quarter of 2010
11. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2017)... Md. , May 3, 2017  Kalorama ... growth of nine percent next year and this ... organ and hematopoietic stem cell (HSCT) or bone ... donor. Molecular testing technologies are well-suited for this task. ... market research publisher Kalorama Information. The various PCR-based ...
(Date:5/2/2017)... WASHINGTON and NEW YORK ... 2017 As the leading distributor of market ... with European Med Tech Reimbursement Consulting AB ... Med Tech Reimbursement Consulting AB,s proprietary market analyses through ... business professionals around the world easy access to complete ...
(Date:5/2/2017)... PASO ROBLES, Calif. , May 2, 2017  Bayer ... have received grants from Healthy Hives 2020, a $1 million ... in the U.S. by the end of 2020. ... Dr. Olav Rueppell , University of North Carolina at ... currently available honey bees; Dr. Edmund ...
Breaking Medicine Technology:
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... Axiad ... organizations, today announced CIO Applications magazine has named the company a “Top 25 ... use of the Cloud to help organizations simply and proactively address potential cybersecurity threats ...
(Date:5/23/2017)... ... May 23, 2017 , ... PM360, the ... sectors, today announced the winners of its 3rd Annual ELITE Awards. The ELITE ... people in the healthcare industry today. , Out of more than 500 submissions, ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms Viability of ... Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price to ... ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, 2017 ...
(Date:5/23/2017)... ... 23, 2017 , ... The National Council on Strength and ... the organization’s Certified Strength Coach credential has earned accreditation from the National Commission ... the competency of qualified candidates for jobs in the Strength and Conditioning profession. ...
(Date:5/23/2017)... ... May 23, 2017 , ... The Gallery of ... Sadati, is pleased to announce a new treatment option called Vivace Microneedling. This ... face, neck, and body through a virtually pain-free, non-surgical treatment. Vivace Microneedling combines ...
Breaking Medicine News(10 mins):